Fetal CPR at Term for Prediction of Adverse Neonatal Outcome in Pregnancies Complicated by GDM

Gestational Diabetes Clinical Trial

Official title:

Fetal Cerebroplacental Ratio at Term for Prediction of Adverse Neonatal Outcome in Pregnancies Complicated by Gestational Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05852639
• Other study ID #: MD-329-2022
• Status: Recruiting
• Start date: November 30, 2022
• Est. completion date: April 2024

Study information

• Verified date: May 2023
• Source: Cairo University
• Contact: Mariam Gabr
• Phone: +201227051013
• Email: mariam.a.gabr[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to evaluate fetal cerebroplacental ratio at term and its relation to adverse neonatal outcome in patients with gestational diabetes. The main question[s] it aims to answer are:

• To evaluate the efficacy (sensitivity & specificity) of fetal cerebroplacental ratio at term in prediction of adverse neonatal outcome in pregnancies complicated by gestational diabetes

• To evaluate the difference in fetal cerebroplacental ratio in patients treated by insulin & those on metformin

• to evaluate the incidence of adverse neonatal outcome in patients treated by insulin & those on metformin.

Participants will undergo ultrasound and doppler study at 37 weeks & every two weeks thereafter till delivery. Neonatal assessment will be done after delivery to exclude adverse outcomes.

Description:

pregnant females in the reproductive age, pregnant ≥37 weeks, who were diagnosed with gestational diabetes by routine screening at 24-28 weeks, and are on metformin or insulin treatment. Informed consent, to share in the study, will be taken from all participants after describing the aim of the study and the potential hazards.

The patients enrolled in our study will be divided into two equal groups according to their treatment regimens:

(Group A): 130 patients who are on insulin treatment

(Group B): 130 patients who are on metformin

*All participants will be subjected to the following:

A) Full history taking:

Including personal, menstrual, obstetric, present, past & family history. B) Complete Physical Examination (general & local).

C) Investigations:

• Routine baseline investigations:

1. Complete blood picture, Rh typing, liver & kidney functions.

2. HbA1C estimation.

3. Surveillance of maternal diabetes: daily fasting and 2- hour postprandial capillary glucose measurement.

4. Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight (EFW) and amniotic fluid index (AFI) and to exclude fetal anomalies.

• Doppler ultrasonography assessment:

Doppler study and Cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks.To reduce inter-operator variability, a single experienced sonographer will perform all sonograms.

The mode of delivery and the gestational age at delivery will be noted

Early neonatal assessment:

1. 1&5 minutes APGAR score

2. Neonatal blood glucose

3. Neonatal cord blood PH

4. The need for NICU admission

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 260
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Maternal age: 18-40 years

• Diagnosed with gestational DM and are on insulin or metformin treatment.

• Single living pregnancy.

• Gestational age = 37 weeks (confirmed by a reliable date for the last menstrual period and 1st trimester ultrasound scan).

Exclusion Criteria:

• Fetal anomalies.

• Maternal chronic diseases esp. renal disease, epilepsy or CNS lesion.

• Pregnancy induced medical disorders.

• IUGR (EFW below the 10th percentile for gestational age).

• Rupture of membranes or oligohydramnios (AFI < the fifth percentile).

Related Conditions & MeSH terms

• Diabetes, Gestational
• Gestational Diabetes

Intervention

Device:
• Ultrasound
Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks

Locations

Country	Name	City	State
Egypt	Kasr al-ainy hospital, Faculty of Medicine - Cairo University	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy (sensitivity & specificity) of fetal cerebroplacental ratio at term in prediction of adverse neonatal outcome in pregnancies complicated by gestational diabetes		17 months
Secondary	To evaluate the difference in fetal cerebroplacental ratio in both groups		17 months
Secondary	To evaluate the incidence of adverse neonatal outcome in both groups		17 months